📊 TRVI Key Takeaways
Is Trevi Therapeutics, Inc. (TRVI) a Good Investment?
Trevi Therapeutics is a pre-revenue development-stage biotech company with improving loss trends (EPS improved 31.9% YoY) but critically insufficient cash runway of less than 6 months at current -$42.1M annual burn rate against $18.9M in cash reserves. While the strong balance sheet ($183.2M equity, zero debt) and excellent liquidity ratios (19.66x current ratio) are positive, the immediate capital crisis presents existential risk without near-term commercialization success or dilutive equity financing.
Why Buy Trevi Therapeutics, Inc. Stock? TRVI Key Strengths
- Zero long-term debt with pristine capital structure and $183.2M stockholders equity
- Exceptional liquidity position with 19.66x current ratio enabling operational flexibility
- Improving profitability trend with 31.9% YoY improvement in diluted EPS loss magnitude, suggesting potential approach to commercialization or burn rate reduction
TRVI Stock Risks: Trevi Therapeutics, Inc. Investment Risks
- Critically short cash runway of <6 months given -$42.1M annual operating cash burn against $18.9M cash balance
- Zero revenue with no commercialized products creates absolute dependence on external capital or successful pipeline advancement
- Development-stage biotech model with inherent clinical trial failure risk, regulatory uncertainty, and commercialization execution risk
Key Metrics to Watch
- Cash balance trajectory and timing of next capital raise or financing event
- Quarterly operating cash burn rate and any improvement from prior periods
- Pipeline milestone achievements and regulatory approval progress for lead drug candidates
Trevi Therapeutics, Inc. (TRVI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 19.66x current ratio provides a solid financial cushion.
TRVI Profit Margin, ROE & Profitability Analysis
TRVI vs Healthcare Sector: How Trevi Therapeutics, Inc. Compares
How Trevi Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Trevi Therapeutics, Inc. Stock Overvalued? TRVI Valuation Analysis 2026
Based on fundamental analysis, Trevi Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Trevi Therapeutics, Inc. Balance Sheet: TRVI Debt, Cash & Liquidity
TRVI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Trevi Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.47 indicates the company is currently unprofitable.
TRVI Revenue Growth, EPS Growth & YoY Performance
Trevi Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TRVI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Trevi Therapeutics, Inc. (CIK: 0001563880)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TRVI
What is the AI rating for TRVI?
Trevi Therapeutics, Inc. (TRVI) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TRVI's key strengths?
Claude: Zero long-term debt with pristine capital structure and $183.2M stockholders equity. Exceptional liquidity position with 19.66x current ratio enabling operational flexibility.
What are the risks of investing in TRVI?
Claude: Critically short cash runway of <6 months given -$42.1M annual operating cash burn against $18.9M cash balance. Zero revenue with no commercialized products creates absolute dependence on external capital or successful pipeline advancement.
What is TRVI's revenue and growth?
Trevi Therapeutics, Inc. reported revenue of N/A.
Does TRVI pay dividends?
Trevi Therapeutics, Inc. does not currently pay dividends.
Where can I find TRVI SEC filings?
Official SEC filings for Trevi Therapeutics, Inc. (CIK: 0001563880) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TRVI's EPS?
Trevi Therapeutics, Inc. has a diluted EPS of $-0.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TRVI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Trevi Therapeutics, Inc. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TRVI stock overvalued or undervalued?
Valuation metrics for TRVI: ROE of -23.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TRVI stock in 2026?
Our dual AI analysis gives Trevi Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TRVI's free cash flow?
Trevi Therapeutics, Inc.'s operating cash flow is $-42.1M, with capital expenditures of $12.0K.
How does TRVI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -23.3% (avg: 15%), current ratio 19.66 (avg: 2).